TheEdgeResearch
Home / Stocks / MGNX

MacroGenics, Inc. (MGNX)

NASDAQ Healthcare Biotechnology
$1.96 ▼ -1.01%
Market Cap
$125.3M
Sector
Healthcare
Industry
Biotechnology
Beta
1.32
52-Wk Range
1.32-5.08
CEO
Eric Risser
Country
US
Currency
USD

MacroGenics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Rockville, MD, US. The stock last traded at $1.96, down 1.01% on the session, giving a market capitalisation of $125.3M. On trailing twelve-month figures it carries a trailing P/E of -2.42, a net margin of -45.4%. Its beta of 1.32 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-2.42
Price / Sales
1.10
Price / Book
4.97
EV / EBITDA
-0.92
Gross margin
4.2%
Operating margin
-70.2%
Net margin
-45.4%
Return on equity
—
Debt / equity
1.39
Current ratio
2.75
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
293
IPO date
2013-10-10
Headquarters
Rockville, MD, US
About MacroGenics, Inc.

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Comparable companies

MacroGenics, Inc. is most often compared with the following Healthcare names:

CLNNCNTBCNTXCOYAIFRXORMPOVIDSTTKWHWKZNTL
More research on MGNX
MGNX technical analysis MGNX TheEdge Score Compare against peers
Open full interactive analysis & DCF →